Literature DB >> 32961544

Complement component C4 levels in the cerebrospinal fluid and plasma of patients with schizophrenia.

Juan A Gallego1,2,3,4, Emily A Blanco5, Christopher Morell6, Todd Lencz7,6,8, Anil K Malhotra7,6,8.   

Abstract

Abnormalities in the complement system have been described in patients with schizophrenia, with those individuals having greater frequency of complement component 4A (C4A) alleles and higher C4A transcript levels in postmortem brain tissue. Importantly, abnormalities in C4A and other complement molecules have been associated with synaptic pruning abnormalities that occur during neurodevelopment. A few studies have investigated C4 levels in living patients with schizophrenia, but all of them did so using peripheral blood samples. No studies have examined C4 levels in cerebrospinal fluid (CSF), presumably a better biofluid choice given its intimate contact with the brain. Therefore, we report for the first time on C4 levels in CSF and plasma of patients with schizophrenia. In this study, we obtained CSF in 32 patients with schizophrenia spectrum disorders and 32 healthy volunteers and peripheral blood samples in 33 SSD and 31 healthy volunteers. C4 levels were measured using Abcam ELISA assays. Univariate analysis did not show a statistically significant difference in CSF C4 values between groups. However, a multivariable analysis showed a statistically significant increase in CSF C4 levels between groups after adjusting for sex and age. We also observed a high correlation between CSF C4 levels and age. By contrast, plasma C4 levels were not significantly different between groups. CSF and plasma C4 levels were not significantly correlated. Therefore, the use of CSF samples is critical and should be complementary to the use of peripheral blood samples to allow for a comprehensive understanding of complement C4 abnormalities in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32961544      PMCID: PMC8115103          DOI: 10.1038/s41386-020-00867-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  14 in total

1.  C4A mRNA expression in PBMCs predicts the presence and severity of delusions in schizophrenia and bipolar disorder with psychosis.

Authors:  Jennifer K Melbourne; Cherise Rosen; Benjamin Feiner; Rajiv P Sharma
Journal:  Schizophr Res       Date:  2018-02-12       Impact factor: 4.939

2.  Investigation of peripheral complement factors across stages of psychosis.

Authors:  Liliana Laskaris; Andrew Zalesky; Cynthia Shannon Weickert; Maria A Di Biase; Gursharan Chana; Bernhard T Baune; Chad Bousman; Barnaby Nelson; Patrick McGorry; Ian Everall; Christos Pantelis; Vanessa Cropley
Journal:  Schizophr Res       Date:  2018-12-06       Impact factor: 4.939

Review 3.  The complement system in schizophrenia: where are we now and what's next?

Authors:  Julia J Woo; Jennie G Pouget; Clement C Zai; James L Kennedy
Journal:  Mol Psychiatry       Date:  2019-08-22       Impact factor: 15.992

4.  Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning.

Authors:  Carl M Sellgren; Jessica Gracias; Bradley Watmuff; Jonathan D Biag; Jessica M Thanos; Paul B Whittredge; Ting Fu; Kathleen Worringer; Hannah E Brown; Jennifer Wang; Ajamete Kaykas; Rakesh Karmacharya; Carleton P Goold; Steven D Sheridan; Roy H Perlis
Journal:  Nat Neurosci       Date:  2019-02-04       Impact factor: 24.884

5.  Genetically predicted complement component 4A expression: effects on memory function and middle temporal lobe activation.

Authors:  G Donohoe; J Holland; D Mothersill; S McCarthy-Jones; D Cosgrove; D Harold; A Richards; K Mantripragada; M J Owen; M C O'Donovan; M Gill; A Corvin; D W Morris
Journal:  Psychol Med       Date:  2018-01-09       Impact factor: 7.723

Review 6.  Neuronal migration abnormalities and its possible implications for schizophrenia.

Authors:  Kazue Muraki; Kenji Tanigaki
Journal:  Front Neurosci       Date:  2015-03-10       Impact factor: 4.677

7.  Developmental activities of the complement pathway in migrating neurons.

Authors:  Anna Gorelik; Tamar Sapir; Rebecca Haffner-Krausz; Tsviya Olender; Trent M Woodruff; Orly Reiner
Journal:  Nat Commun       Date:  2017-05-02       Impact factor: 14.919

8.  Complement genes contribute sex-biased vulnerability in diverse disorders.

Authors:  Nolan Kamitaki; Aswin Sekar; Robert E Handsaker; Heather de Rivera; Katherine Tooley; David L Morris; Kimberly E Taylor; Christopher W Whelan; Philip Tombleson; Loes M Olde Loohuis; Michael Boehnke; Robert P Kimberly; Kenneth M Kaufman; John B Harley; Carl D Langefeld; Christine E Seidman; Michele T Pato; Carlos N Pato; Roel A Ophoff; Robert R Graham; Lindsey A Criswell; Timothy J Vyse; Steven A McCarroll
Journal:  Nature       Date:  2020-05-11       Impact factor: 49.962

9.  Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population.

Authors:  Mariana Gaya da Costa; Felix Poppelaars; Cees van Kooten; Tom E Mollnes; Francesco Tedesco; Reinhard Würzner; Leendert A Trouw; Lennart Truedsson; Mohamed R Daha; Anja Roos; Marc A Seelen
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

10.  Complement system biomarkers in first episode psychosis.

Authors:  Maja Kopczynska; Wioleta Zelek; Samuel Touchard; Fiona Gaughran; Marta Di Forti; Valeria Mondelli; Robin Murray; Michael C O'Donovan; B Paul Morgan
Journal:  Schizophr Res       Date:  2017-12-24       Impact factor: 4.939

View more
  8 in total

1.  Association of complement component 4 with neuroimmune abnormalities in the subventricular zone in schizophrenia and autism spectrum disorders.

Authors:  Ta-Chung M Mou; Malcolm V Lane; Derek D C Ireland; Daniela Verthelyi; Leonardo H Tonelli; Sarah M Clark
Journal:  Neurobiol Dis       Date:  2022-08-19       Impact factor: 7.046

2.  Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition.

Authors:  Kirsten E J Wesenhagen; Johan Gobom; Isabelle Bos; Stephanie J B Vos; Pablo Martinez-Lage; Julius Popp; Magda Tsolaki; Rik Vandenberghe; Yvonne Freund-Levi; Frans Verhey; Simon Lovestone; Johannes Streffer; Valerija Dobricic; Lars Bertram; Kaj Blennow; Maria Pikkarainen; Merja Hallikainen; Johanna Kuusisto; Markku Laakso; Hilkka Soininen; Philip Scheltens; Henrik Zetterberg; Charlotte E Teunissen; Pieter Jelle Visser; Betty M Tijms
Journal:  Alzheimers Dement (Amst)       Date:  2022-05-06

3.  Schizophrenia risk loci from xMHC region were associated with antipsychotic response in chronic schizophrenic patients with persistent positive symptom.

Authors:  Jiang Li; Akane Yoshikawa; Ney Alliey-Rodriguez; Herbert Y Meltzer
Journal:  Transl Psychiatry       Date:  2022-03-07       Impact factor: 6.222

4.  First Episode Psychosis and Schizophrenia Are Systemic Neuro-Immune Disorders Triggered by a Biotic Stimulus in Individuals with Reduced Immune Regulation and Neuroprotection.

Authors:  Michael Maes; Kitiporn Plaimas; Apichat Suratanee; Cristiano Noto; Buranee Kanchanatawan
Journal:  Cells       Date:  2021-10-28       Impact factor: 6.600

5.  Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives.

Authors:  Evgeny A Ermakov; Mark M Melamud; Valentina N Buneva; Svetlana A Ivanova
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

6.  The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis.

Authors:  Hussein Kadhem Al-Hakeim; Ali Fattah Al-Musawi; Abbas Al-Mulla; Arafat Hussein Al-Dujaili; Monojit Debnath; Michael Maes
Journal:  PLoS One       Date:  2022-10-18       Impact factor: 3.752

7.  Deregulation of complement components C4A and CSMD1 peripheral expression in first-episode psychosis and links to cognitive ability.

Authors:  Alex Hatzimanolis; Stefania Foteli; Pentagiotissa Stefanatou; Angeliki-Aikaterini Ntigrintaki; Irene Ralli; Konstantinos Kollias; Chrysoula Nikolaou; Maria Gazouli; Nikos C Stefanis
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-09       Impact factor: 5.760

Review 8.  New Insights Regarding Diagnosis and Medication for Schizophrenia Based on Neuronal Synapse-Microglia Interaction.

Authors:  Naotaka Izuo; Atsumi Nitta
Journal:  J Pers Med       Date:  2021-05-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.